Genmab and AbbVie clarify EPCORE DLBCL-1 missed sole US overall survival endpoint
Genmab and AbbVie clarify that EPCORE DLBCL-1 missed its sole US overall survival endpoint despite a PFS benefit for epcoritamab.
Pharma & Biotech
Pharma & Biotech
TIVDAK approval gives Zai Lab a sharper China oncology story, but execution risk remains
TIVDAK enters China’s cervical cancer market with survival data. See why Zai Lab’s ADC approval matters beyond oncology headlines.
Pharma & Biotech
How AbbVie’s epcoritamab reshapes the competitive calculus in relapsed diffuse large B-cell lymphoma
AbbVie’s Phase 3 epcoritamab data raise critical questions about survival endpoints and bispecific antibodies in relapsed lymphoma. Read the full analysis.
Pharma & Biotech
Can epcoritamab reshape salvage DLBCL care? Genmab’s Phase 3 data brings regulatory momentum
Genmab’s epcoritamab improved PFS in a Phase 3 DLBCL trial. Find out how this could reshape bispecific monotherapy in aggressive B-cell lymphoma care.
Pharma & Biotech
Genmab ends acasunlimab trials: What it signals about bispecific immunotherapy risk
Genmab ends development of acasunlimab to focus on EPKINLY, petosemtamab, and Rina-S. Find out what this shift means for 4-1BB bispecifics today.